CN104093738B - 抗asic1抗体及其使用 - Google Patents

抗asic1抗体及其使用 Download PDF

Info

Publication number
CN104093738B
CN104093738B CN201380007553.3A CN201380007553A CN104093738B CN 104093738 B CN104093738 B CN 104093738B CN 201380007553 A CN201380007553 A CN 201380007553A CN 104093738 B CN104093738 B CN 104093738B
Authority
CN
China
Prior art keywords
antibody
asic1
antibodies
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380007553.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104093738A (zh
Inventor
L·麦克唐纳
M·高
M·R·莫拉
N·M·阿莱桑德里-哈贝尔
M·L·拉克鲁瓦-福拉丽什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104093738(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN104093738A publication Critical patent/CN104093738A/zh
Application granted granted Critical
Publication of CN104093738B publication Critical patent/CN104093738B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380007553.3A 2012-01-31 2013-01-30 抗asic1抗体及其使用 Active CN104093738B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US61/592,837 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US61/644,038 2012-05-08
US201261692925P 2012-08-24 2012-08-24
US61/692,925 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN104093738A CN104093738A (zh) 2014-10-08
CN104093738B true CN104093738B (zh) 2018-05-18

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380007553.3A Active CN104093738B (zh) 2012-01-31 2013-01-30 抗asic1抗体及其使用

Country Status (33)

Country Link
US (3) US9150648B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3453723B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6302844B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102111941B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104093738B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR089852A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013215254B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2862332C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014002019A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7020877A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1121368T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3453723T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA028647B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2886123T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20211541T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE056335T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL233410A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014CN04645A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3547B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (2) LT2809681T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX358518B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY168748A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ626242A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014501613A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3453723T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2809681T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS62454B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201403222UA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI2809681T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT202100628T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI591073B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34603A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013116296A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62454B1 (sr) 2012-01-31 2021-11-30 Regeneron Pharma Anti-asic1 antitela i njihove upotrebe
US10272154B2 (en) 2014-04-15 2019-04-30 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
EP3702369A1 (en) 2014-05-16 2020-09-02 Ablynx NV Immunoglobulin variable domains
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
BR112020015112A2 (pt) * 2018-01-26 2021-04-06 Regeneron Pharmaceuticals, Inc. Anticorpos anti-tmprss2 e fragmentos que ligam antígenos
KR20220016891A (ko) * 2019-06-04 2022-02-10 상하이테크 유니버시티 친화성-성숙된 항-ASIC1a 항체
CN119080930A (zh) * 2019-07-11 2024-12-06 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
GB2600333A (en) * 2019-07-23 2022-04-27 Univ Shanghai Technology ASICI channel antagonist antibody
JP2022547718A (ja) * 2019-09-13 2022-11-15 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３７１抗体およびその使用
JP2024531149A (ja) * 2021-08-09 2024-08-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症誘発性サイトカイン放出からｔ細胞性腫瘍細胞毒性をデカップリングするタンパク質
EP4396224A1 (en) * 2021-09-02 2024-07-10 Memorial Sloan Kettering Cancer Center Anti-dll3 antibodies and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051349A1 (en) * 2009-10-27 2011-05-05 Ucb Pharma S.A. Antibodies to ion channels
CN102234316A (zh) * 2010-05-07 2011-11-09 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
CA2308014A1 (en) 1997-10-29 1999-05-06 Mcgill University Dna encoding a human proton-gated ion channel and uses thereof
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
CA2538754A1 (en) 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
WO2006038070A2 (en) 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
KR101017301B1 (ko) * 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
KR100990027B1 (ko) * 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
AU2007254831B2 (en) 2006-06-02 2012-03-22 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
WO2008007648A1 (fr) * 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
WO2008007131A2 (en) 2006-07-14 2008-01-17 Medical Research Council Treatment for demyelinating disease
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
ATE483985T1 (de) 2007-04-03 2010-10-15 Ilegusavnid Genetics Resource Mit panikstörungen assoziierte amilorid-sensitive natriumkanäle
EP2392597B1 (en) * 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2009137686A1 (en) * 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
WO2010054010A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
RS62454B1 (sr) 2012-01-31 2021-11-30 Regeneron Pharma Anti-asic1 antitela i njihove upotrebe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051349A1 (en) * 2009-10-27 2011-05-05 Ucb Pharma S.A. Antibodies to ion channels
CN102234316A (zh) * 2010-05-07 2011-11-09 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Distribution, subcellular localiztion and ontogeny of ASIC1 in the mammalian central nervous system;Alvarez de la Rosa, D.等;《Journal of Physiology》;20030101;第546卷(第1期);第841-848页 *

Also Published As

Publication number Publication date
EP3453723B1 (en) 2021-08-11
US20130195878A1 (en) 2013-08-01
EP2809681A1 (en) 2014-12-10
JP6302844B2 (ja) 2018-03-28
KR20140125363A (ko) 2014-10-28
HUE056335T2 (hu) 2022-02-28
CL2014002019A1 (es) 2015-01-16
IL254416A0 (en) 2017-11-30
ES2707599T3 (es) 2019-04-04
LT3453723T (lt) 2021-09-10
WO2013116296A1 (en) 2013-08-08
DK2809681T3 (en) 2019-03-11
US20160002332A1 (en) 2016-01-07
PT3453723T (pt) 2021-09-07
LT2809681T (lt) 2019-02-11
EA201491452A1 (ru) 2014-11-28
PT2809681T (pt) 2019-02-18
SG11201403222UA (en) 2014-07-30
AU2013215254A1 (en) 2014-07-03
IL233410A0 (en) 2014-08-31
BR112014018651A2 (pt) 2017-07-04
HRP20211541T1 (hr) 2021-12-24
SMT202100628T1 (it) 2022-01-10
CA2862332C (en) 2021-05-18
EA028647B1 (ru) 2017-12-29
US10513557B2 (en) 2019-12-24
AR089852A1 (es) 2014-09-24
KR102111941B1 (ko) 2020-05-18
MX2014008541A (es) 2014-10-24
AU2013215254B2 (en) 2017-08-31
CY1124778T1 (el) 2022-11-25
IL254416B (en) 2018-03-29
HK1199269A1 (en) 2015-06-26
HRP20190358T1 (hr) 2019-04-05
TW201335182A (zh) 2013-09-01
UY34603A (es) 2013-07-31
JP2015508063A (ja) 2015-03-16
HUE042531T2 (hu) 2019-07-29
DK3453723T3 (da) 2021-09-13
CO7020877A2 (es) 2014-08-11
RS58439B1 (sr) 2019-04-30
IN2014CN04645A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-18
EP3453723A2 (en) 2019-03-13
PH12014501613B1 (en) 2014-10-13
CA2862332A1 (en) 2013-08-08
EP3453723A3 (en) 2019-04-10
CN104093738A (zh) 2014-10-08
US20180222976A1 (en) 2018-08-09
SI2809681T1 (sl) 2019-04-30
TWI591073B (zh) 2017-07-11
NZ626242A (en) 2017-02-24
CY1121368T1 (el) 2020-05-29
MX358518B (es) 2018-08-24
JO3547B1 (ar) 2020-07-05
PH12014501613A1 (en) 2014-10-13
US9150648B2 (en) 2015-10-06
SI3453723T1 (sl) 2021-11-30
MY168748A (en) 2018-11-30
EP2809681B1 (en) 2018-12-05
RS62454B1 (sr) 2021-11-30
ES2886123T3 (es) 2021-12-16
PL3453723T3 (pl) 2022-01-03
PL2809681T3 (pl) 2019-05-31

Similar Documents

Publication Publication Date Title
CN104093738B (zh) 抗asic1抗体及其使用
JP6563472B2 (ja) 抗ＥｒｂＢ３抗体およびその使用
CN104411722B (zh) 抗egfr抗体及其使用
TWI613218B (zh) ＧＦＲα３之人類抗體及其使用方法
CN103874709B (zh) 抗tie2抗体及其用途
SG178114A1 (en) High affinity human antibodies to human angiopoietin-2
US9371383B2 (en) Anti-ASIC1 antibodies and uses thereof
US20180208656A1 (en) Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof
HK40006818B (en) Anti-asic1 antibodies and uses thereof
HK40006818A (en) Anti-asic1 antibodies and uses thereof
HK1199269B (en) Anti-asic1 antibodies and uses thereof
BR112014018651B1 (pt) Anticorpos anti-asic1, e composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant